Source disclosure: February 26, 2026, 10:30 JST
Japan Tissue Engineering Co.,Ltd. [7774.T]
TOKYO, Feb 26 (Pulse News Wire) – Japan Tissue Engineering CO.,LTD. (7774.T) announced significant management changes effective April 1, 2026.
Key appointments include: - Yasuhiro Aiba promoted to Executive Officer, Pharmaceutical Affairs Director, replacing Kiyotaka Nakamura who now serves as Reliability Assurance Department Head and Pharmaceutical Affairs Director concurrently. - Keisei Sakakibara appointed as Executive Officer, Regenerative Medicine Contract Business Division Manager, previously serving as Regenerative Medicine Contract Business Division Supervisor.
- Masayoshi Hayashi elevated to Executive Officer, Clinical Development Department Manager, moving from Research and Development Department Supervisor to Product Development Department Supervisor. - Other notable promotions include Mihoko Fujita to Manufacturing Department Manager and Production Promotion Department Manager, Shigeo Horuchi to Epithelial Regenerative Medicine Sales Department Manager, Junsei Ito to Sales Planning Department Manager, and Masatoshi Watanabe to Regenerative Medicine Contract Business Department Manager.
These changes reflect the company's strategic realignment aimed at enhancing operational efficiency and driving growth across its regenerative medicine divisions.
AI-translated content. 🟢 Confidence: High See terms • Original filing